Risk Factors for Microscopic Colitis

Sponsor
University of North Carolina, Chapel Hill (Other)
Overall Status
Completed
CT.gov ID
NCT02699333
Collaborator
(none)
346
1
55.8
6.2

Study Details

Study Description

Brief Summary

Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unknown. Understanding the etiology of microscopic colitis is an important step in developing logical interventions to decrease the burden from microscopic colitis. This research could provide critical insights into the etiology of this poorly studied condition.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Microscopic colitis (MC) is a chronic condition that is a common cause of watery diarrhea, particularly in the elderly. The etiology is unknown but widely considered to be an abnormal immune reaction to luminal antigens in predisposed hosts. Drugs and autoimmunity have also been implicated. The aims of the study are: 1) To quantitatively classify microscopic colitis using image analysis microscopy to determine whether the degree of lymphocytic infiltration correlates with etiology, symptoms and prognosis. 2) To investigate the etiology of microscopic colitis by examining medical and lifestyle risk factors including medications, autoimmunity, diet, and smoking 3) To evaluate the association between the adherent microbial flora and MC to assess whether bacterial dysbiosis is linked to presence of MC. As an exploratory aim we will evaluate whether CYP2C19 polymorphisms are more common in purportedly drug-induced disease since the diverse drugs that have been associated with MC are all substrates for this gene.

    To conduct the study the investigators will obtain detailed dietary, medical and lifestyle information on study subjects who undergo complete colonoscopy for diarrhea. The investigators will obtain colon biopsies from the right, transverse and left colon to evaluate adherent bacterial organisms. The investigators will draw blood to evaluate CYP2C19 polymorphisms and for future genetic studies. The prospective design corrects important limitations of prior research on MC. Successful completion of the study aims will improve the understanding of risk factors, set the stage for more scientifically grounded future research, and potentially suggest new interventions for a disease that is currently poorly understood.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    346 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Risk Factors for Microscopic Colitis
    Actual Study Start Date :
    May 1, 2016
    Actual Primary Completion Date :
    Dec 24, 2020
    Actual Study Completion Date :
    Dec 24, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Microscopic colitis cases

    Patients found to have microscopic colitis based on colonic biopsies.

    Controls

    Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.

    Outcome Measures

    Primary Outcome Measures

    1. Microscopic Colitis [Day 1]

      Microscopic colitis defined by increased lymphocytes or collagen

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    35 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    Colonoscopy for diarrhea

    Exclusion Criteria:
    1. Fewer than 4 loose bowel movements per day.

    2. Failure to visualize the entire colon to the cecum or preparation less than good or excellent.

    3. Age under 35 years. There will be no upper age limit.

    4. Inability to understand and cooperate with the interview.

    5. Indication for colonoscopy other than diarrhea.

    6. Prior history of inflammatory bowel disease (Crohn's disease or ulcerative colitis).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of North Carolina Chapel Hill North Carolina United States 27599-7555

    Sponsors and Collaborators

    • University of North Carolina, Chapel Hill

    Investigators

    • Principal Investigator: Robert S. Sandler, MD, University of North Carolina, Chapel Hill

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of North Carolina, Chapel Hill
    ClinicalTrials.gov Identifier:
    NCT02699333
    Other Study ID Numbers:
    • 14-3156
    First Posted:
    Mar 4, 2016
    Last Update Posted:
    Feb 21, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 21, 2021